# US 2022/0033816 A1 · USE OF miRNA 148 CLUSTER AS MARKER FOR DIAGNOSING AND/OR TREATING COGNITIVE IMPAIRMENT-ASSOCIATED DISEASES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033816 A1
- Document ID: US20220033816A1
- Status: Published application
- Kind: A1
- Application number: 17/347,978
- Filed: 2021-06-15
- Published: 2022-02-03
- Earliest claimed: 2020-07-28
- Assignees: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
- Applicants: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
- Inventors: Rui LIU; Zhuorong LI; Hailun JIANG; Li ZENG; Linlin WANG
- Web page: https://patentgrep.com/patent/US20220033816A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/30: Special therapeutic applications
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

The present disclosure discloses use of a miRNA 148 cluster as a marker for diagnosing and/or treating cognitive impairment-associated diseases. The present disclosure provides use of the miRNA 148 cluster in the diagnosis and treatment of cognitive impairment-associated diseases. The expression level of the miRNA 148 cluster is detected using primers for the microRNA through cognitive impairment-associated disease models, and it is found that the expression of the miRNA 148 cluster is significantly reduced during the progression of the cognitive impairment-associated diseases. The miRNA 148 cluster is found to directly target p35 to inhibit hyperphosphorylation of Tau and can be negatively regulated by the upregulated PTEN in AD pathology. Upregulation of miRNA 148 cluster improves the cognitive dysfunction and inhibit the hyperphosphorylation of Tau in AD pathology, in which the PTEN/Akt/CREB and p35/CDK signaling pathways play a key role.

## Claims

### Claim 1

A product with an active ingredient of a miRNA 148 cluster or an expression promoter thereof, wherein, use of the product comprises the following (a), (b), (c) and/or (d):
(a) inhibiting Tau phosphorylation;
(b) alleviating neurodegeneration and providing a neuroprotective effect;
(c) diagnosing and/or treating cognitive impairment-associated diseases; and
(d) reducing the expression of p35, p25, and CDK5.

### Claim 2 (depends on 1)

The product according to claim 1, wherein the miRNA 148 cluster or the expression promoter thereof is used in the following (a), (b), (c), and/or (d):
(a) preparation of a substance that can inhibit phosphorylation of Tau;
(b) preparation of a substance that can alleviate neurodegeneration and has a neuroprotective effect;
(c) preparation of a substance for diagnosing and/or treating cognitive impairment-associated diseases; and
(d) preparation of a substance for reducing the expression of p35, p25, and cyclin-dependent kinase 5 (CDK5).

### Claim 3 (depends on 1)

The product according to claim 1, wherein,
the miRNA 148 cluster is selected from hsa-miR-148a, with a nucleotide sequence shown in SEQ ID NO. 1; and
the miRNA148 cluster is selected from hsa-miR-148a-3p, with a nucleotide sequence shown in SEQ ID NO. 2.

### Claim 4 (depends on 1)

The product according to claim 1, wherein,
the product for diagnosing cognitive impairment-associated diseases is a detection kit;
the detection kit comprises primers of the miRNA148 cluster; and the assay kit is used to diagnose cognitive impairment-associated diseases, predict the risk of developing cognitive impairment-associated diseases, or predict the outcome of cognitive impairment-associated diseases in patients suffering from or at risk of developing cognitive impairment-associated diseases.

### Claim 5 (depends on 4)

The product according to claim 4, wherein,
the primer is used to determine an expression level of the miRNA 148 cluster in a sample.

### Claim 6 (depends on 1)

The product according to claim 1, wherein,
the expression level of the miRNA 148 cluster is based on an expression level of the miRNA 148 cluster in a patient and a reference expression level of the miRNA 148 cluster in a healthy subject; and
if the expression level of the miRNA 148 cluster is significantly lower than the reference expression level of the miRNA 148 cluster in a healthy subject, it indicates that the patient has or is at risk of developing a cognitive impairment-associated disease.

### Claim 7 (depends on 1)

The product according to claim 1, wherein,
the expression level of the miRNA 148 cluster is determined by a sequencing-based method, an array-based method, or a PCR-based method.

### Claim 8 (depends on 1)

The product according to claim 1, wherein,
the expression promoter of the miRNA 148 cluster is at least one of a reagent, a medicament, a preparation, and a gene sequence that promotes the expression or activation of Akt, a reagent, a medicament, a preparation, and a gene sequence that promotes the expression or activation of cAMP-response element binding protein (CREB), and a reagent, a medicament, a preparation, and a gene sequence that inhibits the expression or activation of PTEN;
the Akt and CREB up-regulate the expression of the miRNA 148 cluster; and the PTEN down-regulates the expression of the miRNA 148 cluster.

### Claim 9

Use of an agonist for a miRNA 148 cluster in the preparation of a medicament for treating cognitive impairment-associated diseases.

### Claim 10

Use of a long non-coding RNA (lncRNA) interactive with a miRNA 148 cluster in the preparation of a medicament for treating cognitive impairment-associated diseases.
